Fig. 1From: First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimensCD4-cell and viral load monitoring, ART regimens, and resistance profiles since ART-initiationBack to article page